Researchers evaluated the microbial characteristics driving ankylosing spondylitis pathogenesis, and they examined the effects of tumor necrosis factor inhibitor therapy on the microbiome.
Researchers examined the changes in the presentation of incident gout in the last20 years and determined risk for subsequent gout flares after an initial gout attack.
Researchers reviewed the recently released Lyme disease guidelines and addressed their appropriate inclusion of and association with psychiatric illnesses.
The Infectious Diseases Society of America, the American Academy of Neurology, and the American College of Rheumatology have released a draft of their joint clinical practice guidelines for the management of Lyme disease.
Systemic anticoagulation was found to improve quality-adjusted life years among patients with idiopathic pulmonary arterial hypertension but not among those with connective tissue disease-associated pulmonary arterial hypertension.
Given the limited data is available on bone health of patients with NMOSD-AQP4, researchers aimed to investigate their risk for fracture and bone loss.
Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.
Perrigo announced that the FDA has approved the abbreviated New Drug Application for its over-the-counter diclofenac sodium topical gel 1% for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle or knee in adults ≥18 years old.
Prescription fill patterns of medications associated with potential benefits, as well as possible harms, during the COVID-19 pandemic described in new analysis.
Apremilast used for the treatment of psoriasis or psoriatic arthritis is not associated with a high risk of incident treated depression, anxiety, or anxiety plus depression.
A recently published report presented at the 2019 AIBD Annual Meeting in Orlando, FL, discussed the case of a patient who developed ulcerative colitis (UC) following treatment with Secukinumab for her psoriatic arthritis and highlighted a novel approach for the management of both of her conditions simultaneously.
The Patient Experienced Symptom State (PESS) global outcome measure may be a simple tool to identify disease remission status in patients with rheumatoid arthritis.
Researchers investigated the association between rheumatologist visits within 6 weeks of symptom onset and improved long-term disease outcomes in rheumatoid arthritis.
